MicroRNAs as Guardians of the Prostate: Those Who Stand before Cancer. What Do We Really Know about the Role of microRNAs in Prostate Biology?

被引:18
作者
Andl, Thomas [1 ]
Ganapathy, Kavya [1 ]
Bossan, Alexia [1 ]
Chakrabarti, Ratna [1 ]
机构
[1] Univ Cent Florida, Burnett Sch Biomed Sci, Orlando, FL 32816 USA
关键词
microRNAs; prostate biology; prostate cancer; androgen receptor signaling; INHIBITS CELL-PROLIFERATION; SMOOTH-MUSCLE-CELLS; ANDROGEN RECEPTOR; TUMOR-SUPPRESSOR; DOWN-REGULATION; MESENCHYMAL TRANSITION; STEM-CELLS; EXPRESSION; PROMOTES; MIRNA;
D O I
10.3390/ijms21134796
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer is the second leading cause of cancer-related deaths of men in the Western world. Despite recent advancement in genomics, transcriptomics and proteomics to understand prostate cancer biology and disease progression, castration resistant metastatic prostate cancer remains a major clinical challenge and often becomes incurable. MicroRNAs (miRNAs), about 22-nucleotide-long non-coding RNAs, are a group of regulatory molecules that mainly work through post-transcriptional gene silencing via translational repression. Expression analysis studies have revealed that miRNAs are aberrantly expressed in cancers and have been recognized as regulators of prostate cancer progression. In this critical review, we provide an analysis of reported miRNA functions and conflicting studies as they relate to expression levels of specific miRNAs and prostate cancer progression; oncogenic and/or tumor suppressor roles; androgen receptor signaling; epithelial plasticity; and the current status of diagnostic and therapeutic applications. This review focuses on select miRNAs, highly expressed in normal and cancer tissue, to emphasize the current obstacles faced in utilizing miRNA data for significant impacts on prostate cancer therapeutics.
引用
收藏
页码:1 / 33
页数:33
相关论文
共 237 条
[1]   Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue [J].
Aakula, Anna ;
Kohonen, Pekka ;
Leivonen, Suvi-Katri ;
Makela, Rami ;
Hintsanen, Petteri ;
Mpindi, John Patrick ;
Martens-Uzunova, Elena ;
Aittokallio, Tero ;
Jenster, Guido ;
Perala, Merja ;
Kallioniemi, Olli ;
Ostling, Paivi .
EUROPEAN UROLOGY, 2016, 69 (06) :1120-1128
[2]   The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas [J].
Adams, Brian D. ;
Parsons, Christine ;
Slack, Frank J. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (06) :737-753
[3]   Predicting effective microRNA target sites in mammalian mRNAs [J].
Agarwal, Vikram ;
Bell, George W. ;
Nam, Jin-Wu ;
Bartel, David P. .
ELIFE, 2015, 4
[4]   Plasma microRNA signature is associated with risk stratification in prostate cancer patients [J].
Al-Qatati, Abeer ;
Akrong, Christine ;
Stevic, Ines ;
Pantel, Klaus ;
Awe, Julius ;
Saranchuk, Jeff ;
Drachenberg, Darrel ;
Mai, Sabine ;
Schwarzenbach, Heidi .
INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (06) :1231-1239
[5]   Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer [J].
Albino, Domenico ;
Civenni, Gianluca ;
Dallavalle, Cecilia ;
Roos, Martina ;
Jahns, Hartmut ;
Curti, Laura ;
Rossi, Simona ;
Pinton, Sandra ;
D'Ambrosio, Gioacchino ;
Sessa, Fausto ;
Hall, Jonathan ;
Catapano, Carlo V. ;
Carbone, Giuseppina M. .
CANCER RESEARCH, 2016, 76 (12) :3629-3643
[6]   Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients [J].
Avgeris, Margaritis ;
Stravodimos, Konstantinos ;
Scorilas, Andreas .
BIOLOGICAL CHEMISTRY, 2014, 395 (09) :1095-1104
[7]   Kinetic Analysis Reveals the Fate of a MicroRNA following Target Regulation in Mammalian Cells [J].
Baccarini, Alessia ;
Chauhan, Hemangini ;
Gardner, Thomas J. ;
Jayaprakash, Anitha D. ;
Sachidanandam, Ravi ;
Brown, Brian D. .
CURRENT BIOLOGY, 2011, 21 (05) :369-376
[8]   MicroRNA-targeting therapeutics for hepatitis C [J].
Baek, Jihae ;
Kang, Soowon ;
Min, Hyeyoung .
ARCHIVES OF PHARMACAL RESEARCH, 2014, 37 (03) :299-305
[9]   Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors [J].
Beg, Muhammad S. ;
Brenner, Andrew J. ;
Sachdev, Jasgit ;
Borad, Mitesh ;
Kang, Yoon-Koo ;
Stoudemire, Jay ;
Smith, Susan ;
Bader, Andreas G. ;
Kim, Sinil ;
Hong, David S. .
INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) :180-188
[10]   DGCR8 is essential for tumor progression following PTEN loss in the prostate [J].
Belair, Cassandra D. ;
Paikari, Alireza ;
Moltzahn, Felix ;
Shenoy, Archana ;
Yau, Christina ;
Dall'Era, Marc ;
Simko, Jeff ;
Benz, Christopher ;
Blelloch, Robert .
EMBO REPORTS, 2015, 16 (09) :1219-1232